Related Experiment Video

Updated: Jan 20, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K

Non-coding RNAs as Mediators of Tamoxifen Resistance in Breast Cancers

Mohd Farhan1, Mohammad Aatif2, Prasad Dandawate3

  • 1Department of Biology, College of Basic Sciences, King Faisal University, Al-Ahsa, Saudi Arabia. mfarhan@kfu.edu.sa.

Advances in Experimental Medicine and Biology
|August 29, 2019
PubMed

Insights

Estrogen receptor-positive breast cancer patients often develop tamoxifen resistance. Non-coding RNAs, including microRNAs and long non-coding RNAs, are emerging as key regulators influencing tamoxifen sensitivity and predicting relapse.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Estrogen receptor-positive breast cancer is common and typically treated with tamoxifen.
  • Tamoxifen resistance, both de novo and acquired, presents a significant clinical challenge.
  • Non-coding RNAs are increasingly recognized for their role in cancer development and treatment response.

Purpose of the Study:

  • To review the role of non-coding RNAs in tamoxifen resistance in breast cancer.
  • To explore microRNAs and long non-coding RNAs as mediators and predictors of tamoxifen resistance.
  • To provide a perspective on how these molecules influence tamoxifen sensitivity.

Main Methods:

  • Literature review of in vitro and in vivo studies.
  • Analysis of clinical sample data.
  • Evaluation of research on microRNAs and long non-coding RNAs.

Main Results:

  • Non-coding RNAs, including microRNAs and long non-coding RNAs, play a crucial role in modulating tamoxifen resistance.
  • Evidence from various studies supports their function as mediators of resistance.
  • These non-coding RNAs can serve as predictors of disease relapse in breast cancer patients.

Conclusions:

  • Non-coding RNAs are significant determinants of tamoxifen sensitivity and resistance.
  • Targeting non-coding RNAs may offer novel therapeutic strategies for overcoming tamoxifen resistance.
  • Further research into non-coding RNAs is essential for improving breast cancer treatment outcomes.
Keywords:
Breast cancerLong non-coding RNAsTamoxifen resistancemiRNAs

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.9K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.5K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.4K
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Nursing Code of Ethics01:29

Nursing Code of Ethics

The Nursing Code of Ethics sets the ethical benchmark for the profession, and guides nurses in ethical analysis and decision making at the societal, organizational, and clinical levels. The code encompasses showing compassion and respect for the patient, their families, and communities in all circumstances while committing to providing patient-centered care. In addition, the code states that nurses must advocate for the patient by defending a cause or recommendation to protect their rights,...
4.3K